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ABSTRACT. Objectives. To further define the clinical 
spectrum of the disease for pediatric and metabolic spe­
cialists, and to suggest that the general pediatrician and 
pediatric neurologist consider succinic semialdehyde de­
hydrogenase (SSADH) deficiency in the differential di­
agnosis of patients with (idiopathic) mental retardation 
and emphasize the need for accurate, quantitative or­
ganic acid analysis in such patients.
Patients. The clinical features of 23 patients (20 fam­
ilies) with SSADH deficiency (4-hydroxybutyric acid­
uria) are presented. The age at diagnosis ranged from 3
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months to 25 years in the 11 male and 12 female patients; 
consanguinity was noted in 39% of families.
Outcome Measurements. The following abnormali­
ties were observed (frequency in 23 patients): motor de­
lay, including fine-motor skills, 78%; language delay, 
78%; hypotonia, 74%; mental delay, 74%; seizures, 48%; 
decreased or absent reflexes, 39%; ataxia, 30%; behavioral 
problems, 30%; hyperkinesis, 30%; neonatal problems, 
26%; and electroencephalographic abnormalities, 26%. 
Associated findings included psychoses, cranial mag­
netic resonance or computed tomographic abnormalities, 
and ocular problems in 22% or less of patients. Therapy 
with vigabatrin proved beneficial to varying degrees in 
35% of the patients. Normal early development was 
noted in 30% of patients.
Conclusions. Our data imply that two groups of pa­
tients with SSADH deficiency exist, differentiated by the 
course of early development Our recommendation 
would be that accurate, quantitative organic acid analysis 
in an appropriate specialist laboratory be requested for 
any patients presenting with two or more features of 
mental, motor, or language delay and hypotonia of un­
known cause. Such analyses are the only definitive way 
to diagnose SSADH deficiency; the diagnosis can be 
confirmed by determination of enzyme activity in white 
cells from whole blood. We think that increased use of 
organic acid determination w ill lead to increased diag­
nosis of SSADH deficiency and a more accurate repre­
sentation of disease frequency. As additional patients are 
identified, we should have a better understanding of 
both the metabolic and clinical profiles of SSADH defi­
ciency. Pediatrics 1997;99:567-574; mental retardation, 
succinic semialdehyde dehydrogenase deficiencyT 4-hy­
droxy butyric aciduria, hypotonia, ataxia.
ABBREVIATIONS. SSADH, succinic semialdehyde dehydroge­
nase; GABA, 7-aminobutyric acid; MRI, magnetic resonance im­
aging; EEG, electroencephalogram; CT, computed tomography; 
EMG, electromyography.
Succinic semialdehyde dehydrogenase (SSADH, 
EC 1.2.1.24) deficiency (4-hydroxybutyric aciduria, 
McKusick 271980) is a rare inherited defect in the 
degradative pathway of the inhibitory neurotrans­
mitter 7-aminobutyric acid (GABA).1 Approximately 
40 patients have been reported, with a wide variabil­
ity in clinical phenotype.2 This disorder is unusual 
because it is a defect of neurotransmitter metabolism
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TABLE. Clinical Findings in 23 Patients With Succinic Semialdehyde Dehydrogenase Deficiency




Neonatal Normal Early Mental Motor Language Ataxia 
Problems Development Delay Delay Delay
Hypotonia
A.E.-M.t M 4 mo Palestinian- + — + — — — n
Lebanese
A.F. M 25 y Chinese — — +§ +§ + t —
B.E. F 5 y Turkish — — — + t + i n — —
B.H. M 19 mo Syrian + — — + + t + + t
C.S. F 10 mo American +§ + Mildt MildJ — —
D.E. M 7 y German — — — + t + + — +
E.G. F 8 y Dutch + + t + + + t
I.C. M 2 y American- — +§ + - - — —
European
I.O. F 11 mo Turkish + + t + + t
J.E.Y.II F 6 y Korean +§ + + t + / - §
J.I.Y.II F 8 y Korean — + + t — —
ICS. F 2 y Turkish + + t + +
M.H.t M 3 mo Saudi + + + + + t
M.S. F 3V2 y Pakistani + +§ + + + Developed
later
M.W. M 4 ]/2 y American- — +§ — — + Î
European
N.O. M 12 y Bulgarian + + / —§
P.F. F 4 y Inuit + i + + /  —
(Greenland)
P.L. M 4 mo American- — +*§ + t +
European
P.S.H.l F Postmortem Indian — — — + t + +
P.S.Ï F 9lA y Indian — — + + t + t +$
P.V.Ï F 3 y Indian — -g — + + t + + + t
T.A. M 6% y Lebanese + — +Î +
Y.A. M 2 y Turkish + — + t + t + —
* MRI indicates magnetic resonance imaging; and CT, computed tomography, 
t  First cousins.
$ Presenting signs.
§ See "Case Reports."
|| Siblings.
1  Siblings.
as well as one in which the accumulated diagnostic 
metabolite, 4-hydroxybutyric acid, also has unique 
neuropharmacologic properties3 (Table). Most pa­
tients show some degree of retardation in psychomo­
tor and language development/ often associated with 
hypotonia and/or ataxia. The difficulty lies in detec­
tion, because the disorder presents with such non­
specific neurologic features that most neurologic or 
metabolic specialists are unlikely to request organic 
acid quantification. Without such analyses, these pa­
tients remain undiagnosed. Some of the patients we 
studied were initially examined for cerebral palsy or 
fragile X syndrome. Our review of these patients led 
us to suggest the existence of two distinct groups of 
SSADH-deficient patients, those with normal early 
development and others with developmental prob­
lems during infancy.
METHODS
Urinary organic acid analysis identified increased excretion of 
4-hydroxybutyric acid in all patients (except P.S.H., who died at 13 
years of age and whose diagnosis was deduced based on clinical 
features similar to those of her diagnosed siblings). Other metab­
olites consistent with the further metabolism of 4-hydroxybutyric 
acid, including 3-hydroxypropionic acid, 3,4-dihydroxybutyric 
acid, and glycolic and 4,5-dihydroxyhexanoic acids,4 were identi­
fied in increased amounts in the urine of many patients. Defi­
ciency of SSADH activity was demonstrated in extracts of lym­
phocytes, lymphoblasts, and/or fibroblasts derived from all 
patients (except P.S.H.).5
CASE REPORTS (See Table)
Unless otherwise stated, all pregnancies and deliveries were 
normal, and children were nondysmorphic with normal somatic 
growth and no associated movement disorder other than ataxia. 
Pertinent abnormalities are given.
A.E.-M.
A.E.-M. was the third child born to consanguineous (first cous­
ins) Palestinian-Lebanese parents and first cousin to M.H. At 4 
months of age he presented with generalized hypotonia, which 
was more pronounced in the upper extremities. Hypertelorism 
and epicanthal folds were evident. He was almost develop men­
tally and mentally normal by the age of 11 months, having only 
mild hypotonia and moderate hepatomegaly.
A.F.
A.F. first presented at 25 years of age. He was born to noncon- 
sanguineous Chinese parents. His early cognitive and language 
development were normal, with first words at 10 months and full 
sentences by 2 years of age. His motor milestones were delayed; he 
did not walk until 2 years of age.
At 3 to 5 years of age, A.F. was described as lacking coordina­
tion, motor control, and social skills. He entered primary school 
but repeated the first grade. A psychologic evaluation, conducted 
at 9 years of age in the United States, determined that the patient
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Neuroimaging* Carnitine Treatment with 
Vigabatrin
A.E.-M.t —
A.F. Normal + + Normal MRI normal Ineffective
B.E. +§ — — Ineffective
B.H. Absent MRI normal Effective§
C.S. + Normal MRI§
D.E. Normal — 4- + — + / - § Abnormal CT§ Low Effective









K.S. Decreased — — Probably
ineffective
M.H.t Absent§ Effective§
U S, Normal + +t§ Normal CT§ Effective
M.W. Normal Normal CT normal Low
N.O. + Abnormal§ MRI probably Effective§
normal?
P.F. Decreased§ +§
P.L. Absent Normal MRI normal Very effective
P.S.H.Ï Decreased -f- — +§ Abnormal§
P.S.Ï Decreased — + #ii 11 +§ Abnormal MRI normal Ineffective§
P.V.l Decreased — + — Abnormal CT normal 1
TA. Decreased — + — Normal CT§ MRI
normal
Y.A. Normal +§ *+*§ +§ Abnormal CT normal Ineffective
had minimal brain dysfunction. He was then placed in a special 
education program. During adolescence he had grand mal sei­
zures but has remained seizure-free while taking carbamazepine 
(Tegretol) and primidone (Mysoline),
At 22 years of age, after completion of a special education 
program in the United States, the patient returned to Hong Kong 
and began to have symptoms of psychosis and hallucinations/ 
which were successfully treated with haloperidol (Haldol). Ge­
netic evaluation at 25 years of age revealed an uncooperative, 
psychotic, bilingual man with tall stature, macrocephaly, and a 
long, triangular face. He had a complex partial seizure disorder. 
Neurologic examination was nonfocal, cranial magnetic resonance 
imaging (MRI) showed no abnormalities, and the electroencepha- 
lographic background was diffusely slow. Vigabatrin therapy was 
ineffective.
B.E.
B.E. was born to nonconsanguineous Turkish parents. Her psy­
chomotor development was retarded; she walked at 30 months 
with an unsteady gait. Developmental tests at 5 years of age 
placed her at a 15- to 18-month developmental level. Her speech 
development was poor; her vocabulary consisted of only a few 
words. Neurologic examination results were normal and did not 
show ataxia or hypotonia. Alternating strabismus was noted. Vi­
gabatrin therapy, attempted for 2 months without clinical effect, 
was discontinued.
B.H.
B.H., a Syrian boy born to consanguineous parents (cousins), 
presented at 19 months of age for evaluation of hypotonia since
the age of 2 months. He has three siblings who are well and have 
no developmental problems. The mother received antibiotics and 
benzodiazepines for leg pain during the fifth and sixth months of 
pregnancy. The child had a history of recurrent respiratory dis­
tress and had three previous hospital admissions for chest infec­
tions, one associated with tonic-clonic movements (which may 
have been related to an aminophylline overdose). Developmen- 
tally, he had no formed words at 19 months. Although he was 
slow to feed, there were no problems with swallowing or vomit­
ing. He had extreme hypotonia with marked head lag, laxity of 
ligaments, and absent reflexes.
A muscle biopsy revealed nonspecific type 2 atrophy. MRI 
showed no abnormalities and a minor increase in signal in the 
white matter posterolateral to the lateral ventricles,
After starting vigabatrin therapy, the patient made slow but 
definite improvement. Of note was the immediate cessation of 
hospital admissions for respiratory infections. The patient's 
breathing remained normal, he became more responsive and play­
ful, and his head control improved; however, he remained hypo­
tonic and developmentally delayed. At 7>h years of age, he sat on 
his own and began to crawl, although his speech consisted of 
monosyllables. At 3 years of age, he crawled on all four limbs but 
remained hypotonic and areflexic.
C.S.
C.S., an American-European girl, presented for evaluation at 10 
months of age. She was born after a pregnancy complicated by 
hyperemesis gravidarum requiring total parenteral nutrition and 
preterm labor at 32 weeks7 gestation. At 7 months of age, she was 
admitted to the hospital after an accident in which she sustained
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a subgaleal hematoma and a right parietal skull fracture, with 
resulting subtle left hemiparesis. Early development was normal; 
she rolled at 6 months and sat alone at 10 months.
She had a generalized seizure at 11 months of age. An electro­
encephalogram (EEG) was normal; MRI of the brain was reported 
with diffuse hyperintensity in the deep subcortical white matter, 
most likely reflecting some type of dysmyelination or demyelinat- 
ing process.
Her examination was significant for subtle signs of left hemi­
paresis. She had mild developmental delay. She had good move­
ment of all extremities and good muscle tone and coordination,
D.E.
D.E. presented at 7 years of age. This German boy had the 
developmental age of 7>/z to 3 years with respect to perception, 
fine-motor activity, social behavior, and language comprehension. 
His expressive language abilities were even more developmen- 
tally retarded. Hyperactivity limited his concentration span to less 
than 2 minutes. He may have had a few very short astatic seizures. 
The EEG showed an abnormal background rhythm with multifo­
cal sharp and slow-wave foci over both hemispheres, which were 
more pronounced in the frontal and occipital regions. Neuroim­
aging computed tomography (CT) showed that the left ventricle 
was slightly enlarged; no other brain anomalies were detectable, 
and the cerebrospinal fluid was normal. The patient's plasma 
showed a deficiency of carnitine with a total carnitine level of 4.9 
jU-mol/L.
The patient had slight hypertrophy of the left cardiac ventricle. 
Vigabatrin treatment was given with increasing doses of up to 
1250 m g/d (100 mg/kg per day). The medication was well toler­
ated and led within 1 month to a reduction of hyperactivity and an 
improvement in concentration and cooperation.
E.G.
E.G., an 8-year-old Dutch girl, presented with mental retarda­
tion and epilepsy. Her parents were consanguineous (first cous­
ins). She walked at 15 months, but speech development was much 
delayed. The first grand mal seizure occurred when she was 6 
years old. She was admitted to a school for severely retarded 
children.
Medical examination at 8 years of age showed mild, general­
ized hypotonia with a flexed gait and poor associated arm move­
ments. No pathologic reflexes could be elicited. Ophthalmologic 
and hearing examinations did not reveal any abnormalities. She 
could follow only simple instructions and had poor verbal abili­
ties.
The EEG and MRI did not reveal any abnormalities. Laboratory 
analysis showed normal cerebrospinal fluid and normal chromo­
somes. The patient was treated with vigabatrin at a dose of 500 
mg/d. After 20 months, a follow-up examination showed that her 
condition improved, and she no longer had seizures.
I.C.
I.C., an American boy born to nonconsanguineous parents of 
European heritage, was hospitalized at 2 months of age for eval­
uation of a 1-month history of chronic bloody diarrhea with mu­
cus, which subsequently resolved. He underwent surgery for bi­
lateral strabismus at IS months. Developmentally, he completed 
all gross-motor, fine-motor, and language milestones up to 1 year 
of age.
Before he started walking independently (11 to 12 months of 
age) he had an apparent lack of balance, with frequent falling and 
bumping into objects. At 23 months he sustained a head injury in 
a fall; 3 weeks later he was evaluated for ataxia. Developmentally, 
the patient had a 30-word vocabulary but did not combine words. 
He was able to climb stairs, used a cup and spoon, assisted with 
dressing, and scribbled with a pencil on paper. He exhibited 
appropriate social interaction with the ability to follow multiple- 
step commands.
At examination he had a vascular telangiectasia of bulbar con­
junctiva with no cutaneous telangiectasia and no other neurocu- 
taneous stigmata. Neurologic examination revealed optokinetic 
nystagmus present in both horizontal directions and ratchety 
tracking of objects with both eyes. The patient had normal 
strength in all extremities with normal muscle bulk and normal to 
slightly diminished muscle tone throughout his body. His stance
was slightly broad based for his age, with a tendency to walk on 
Ms toes; his gait was clearly ataxic without a directional compo­
nent. He fell frequently when attempting to walk, run, or stoop to 
recover objects. The patient also had symmetric appendicular 
ataxia with associated dysmetria. No tremor was present, and 
deep-tendon reflexes were normal.
MRI the brain showed no abnormalities. Physical therapy eval­
uation placed him at an 18- to 22-month motor development level. 
There was spontaneous improvement of his truncal and gait atax­
ia; he did not fall when he walked, ran, or stooped to recover 
objects. At 32 months, his motor skills were progressing, his 
memory was good, and he was speaking in short sentences.
Family history was significant for a maternal sister with hydro­
cephalus and developmental delay who died at 33 years of age. In 
addition, a paternal cousin reportedly had developmental delay of 
uncertain cause.
The patient started receiving vigabatrin at 50 mg/kg per day. 
While receiving vigabatrin therapy, the patient's ataxia improved, 
along with other aspects of his development, which were docu­
mented by neuropsychologic studies before and after treatment. 
The patient has had no adverse affects from vigabatrin therapy.
I .O .
LO. presented at 11 months of age for evaluation. She was born 
to consanguineous parents of Turkish descent and has two older, 
healthy siblings.
At 5 months, the infant had febrile pneumonia accompanied by 
seizures. Her EEG and cranial sonogram were normal, and her 
recovery was uncomplicated. At 8 months of age, she had notice­
able motor development retardation, muscular hypotonia, and a 
low activity level. In addition, physical examination revealed hep­
atomegaly. MRI of the brain was consistent with that of a 6-month- 
old with a slightly widened subarachnoidal space. After diagnosis, 
vigabatrin therapy was started with a 250-mg dose three times a 
day.
Two months after the initiation of vigabatrin therapy, the child 
showed increased agility and stood briefly with help. The hepa­
tomegaly was reduced to normal. After 1 year of treatment with 
vigabatrin and physical therapy, she had muscular hypotonia 
with delayed motor and language development. An increase in 
the vigabatrin dose temporarily caused agitation and screaming. 
The child also received a carnitine supplement because of her 
chronically low carnitine level.
J.E.Y.
J.E.Y. (the Korean female sibling of J.I.Y.) presented at 6 years of 
age. She was born 2 to 3 months premature and had a birth weight 
of approximately 2 lb. The mother reported exposure to dry clean­
ing chemicals during the pregnancy with no other obvious tera­
togenic exposures. The infant was in neonatal intensive care for 2 
months for feeding and growth, during which time there were no 
significant problems associated with prematurity, Early develop­
mental milestones seemed normal; however, her speech was de­
layed with her first words at 2 years of age.
At 6 years of age, the patient had a 20-word vocabulary and 
attended a school for behavioral problems, The patient did not 
have self-injurious behavior to the same degree as her sister 
(J.I.Y.), but she had done a lot of picking at her skin. The patient 
also had some initial hypotonia, although it was minimal.
JXY.
J.I.Y. (the older Korean female sibling of J.E.Y.) presented at 8 
years of age. She reportedly had normal early developmental 
milestones. She walked at approximately 1 year of age, and had 
minimal language development by 2 to 3 years of age. The child's 
development was extremely slow, although she had no loss of 
developmental milestones. She had problems with hyperactivity 
and self-injurious behavior. Her 30-word vocabulary consisted of 
a mixture of English and Korean. She has attended primary school 
the past 3 years.
ICS.
K.S., a Turkish girl, presented at 2 years of age for evaluation of 
delayed development. She has an older sister who is healthy. 
Developmentally, she sat at 10 months and walked at 20 months. 
Clinical examination showed mild muscular hypotonia and hy-
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poreflexia. After the diagnosis of SSADH deficiency, vigabatrin. 
therapy was started.
At 5 years of age, she had received 75 mg /kg vigabatrin for 
more than 24 months with no side effects. There was little progress 
in mental development; her developmental level was approxi­
mately that of a 2-year-old. She spoke only a few German words 
and some short sentences in Turkish. Her physical progress was 
poor, and she had extreme hypotonia, although she was able to 
walk and run slowly.
In 1992, her cranial MRI showed no abnormalities. In February 
1996, symmetric lesions in the globus pallidus, thalamus, and 
brain stem were identified. The clinical profile has not changed 
since the last examination.
M.H.
M.H., a Saudi Arabian boy (first cousin to A.E.-M.), was bom to 
consanguineous parents (first cousins) and has two older, healthy 
siblings.
At 3 months, the patient had generalized hypotonia. At 4 
months, after hospital admission, he was found to have severe 
hypotonia and areflexia with poor head control and was unable to 
raise his head when lying in the prone position. The child seemed 
alert and interested in his surroundings.
Treatment with vigabatrin began at 9 months of age, and the 
dose was gradually increased to 100 mg/kg. He made progress 
while receiving this treatment Although head control remained 
poor, the patient almost sat by himself at 10 months of age. At 16 
months, he walked with support and spoke a few words, and his 
deep-tendon reflexes were normal.
M.S.
M.S., a SV -^year-old Pakistani girl, presented after a generalized 
tonic-clonic seizure associated with fever. During the subsequent 
24 hours the patient seemed confused and frightened, suggesting 
encephalopathy. During the next 48 hours, she showed gradual 
improvement but was then noted to have an unsteady, wide- 
based gait and a tendency to fall. There were also associated 
choreiform movements. The patient continued to improve during 
the ensuing 4 days.
She was bom to consanguineous parents (first cousins) whose 
family history was significant for seizures and mental retardation 
in both the father's and mother's families. The patient has a 
healthy, older male sibling.
As an infant, she was a weak and poor feeder* Her develop­
ment was delayed; she sat unaided at 10 months, rolled at 11 
months, and began to speak at 20 months. Previous neurologic 
evaluation failed to reveal a cause.
Reexamination revealed a marked general intellectual delay. 
Her gait was immature and wide based with normal tone and 
reflexes. The patient had a depigmented patch on her left abdo­
men. CT showed generous subarachnoid spaces around the base 
of the brain, and the fourth ventricle was large. Her EEG was 
normal.
At examination at 4 years 8 months, the patient still had delay 
in her psychomotor development. She was able to string two to 
three words together in both English and her native tongue. Her 
play was immature, reflective of a child 18 months to 2 years of 
age. The patient was not toilet trained. She was generally hypo­
tonic with preserved reflexes. She had frequent involuntary move­
ments, predominantly of the upper limbs.
At 7Vz years the patient had good situational understanding 
and was speaking in simple sentences but was still clumsy. Before 
initiating vigabatrin therapy, the patient had hallucinations, which 
were primarily visual. These stopped when she began treatment. 
With continued treatment, her ataxia also improved.
M.W.
M.W. presented at 4V^  years with significant hypotonia, speech 
delay, motor delay, and moderate mental retardation. His non- 
consanguineous parents were of European ancestry. During early 
infancy, the patient had problems with vomiting associated with 
feeding. The patient underwent surgical correction of pyloric ste­
nosis at 8 weeks of age. Frequent episodes of otitis media required 
multiple myringotomy tube placements and chronic antibiotic 
therapy. He also had frequent episodes of tonsillitis and under­
went a tonsillectomy and adenoidectomy at 4 years of age. At 4Vz
years, he had significant hypotonia, speech delay, motor delay, 
and moderate mental retardation.
The patient had generalized hypotonia at 4 months, and his 
motor development was significantly delayed; he sat at 10 months, 
pulled to stand at 14 months, and walked at 21 months. At TSh 
years the patient was referred to a neurologist, who confirmed 
marked generalized hypotonia without definitive diagnosis. An 
EEG, electromyography (EMG), and CT of the head were normal. 
He had an 18- to 20-word vocabulary but was unable to combine 
words to form sentences. Developmental testing at 2Vz years of age 
determined the patient's gross-motor skills to be at the 15-month 
level, fine-motor skills to be at the 12-month level, receptive lan­
guage skills to be at the 10- to 12-month level, expressive language 
skills to be at the 12- to 14-month level, and overall cognition to be 
at the 12-month level.
Evaluation at 4}/i years revealed that the child was not toilet 
trained and was just learning to run. He was unable to dress 
himself and was unable to use utensils to feed himself, although 
he could finger feed. Speech and language development also were 
delayed significantly. He had a 100-word vocabulary and could 
combine them into two- and three-word sentences. Examination 
was significant for generalized hypotonia and laxity of joints, with 
overall decreased muscle tone but intact deep-tendon reflexes. A 
short (proximal) phalanx on the fifth digit of the right hand was 
also noted.
The patient's plasma showed a deficiency of carnitine, with a 
total carnitine level of 24 nmol/mL (normal, 35 to 50 nmol/mL), a 
free carnitine level of 20 nmol/mL (normal, 30 to 45 nmol/mL), 
and a short-chain acylcarnitine level of 4 nmol/mL (normal, 2 to 6 
nmol/mL). After treatment with L -carn itin e  at 30 m g/kg per day, 
the patient's muscle tone improved dramatically, His speech and 
articulation also improved. Results of a subsequent analysis of 
plasma carnitine levels were within the normal range. Another 
examination after 2 months of L -carn itine  therapy showed essen­
tially normal muscle tone and strength.
N.O.
N.O. was born to nonconsanguineous Bulgarian parents. He 
began walking at 12 months and began speaking at 2 years of age, 
although he never exceeded three-word sentences. His motor 
development was normal, except for problems with small motor 
function and slight ataxia. He was hyperkinetic and was unable to 
concentrate for more than 10 minutes. He did not sleep through 
nights and often ground his teeth during sleep,
At 12 years of age, school entrance testing with nonverbal test 
material revealed a mental development age of 3V2 years. His 
ability to communicate was severely hampered by his language 
disabilities, which included stuttering, repetitions, and a minimal 
vocabulary. Later in his development, he was able to understand 
both German and Bulgarian. He was hyperactive and had some 
minor fine-motor deficits, which occasionally were noticeable. The 
EEG was irregular and slow, and MRI showed only a few non­
specific hyperin.tensive signals in the area of the left globus palli­
dus. High doses of vigabatrin improved the patient's condition 
but induced electroencephalographic changes and seizures. Lower 
doses were better tolerated. A report of vigabatrin therapy in this 
patient is presented elsewhere.6
P.F.
P,F. was bom in Greenland and is ethnically Inuit. Her psy­
chomotor development generally was retarded; she walked at 2Vi 
years of age. At 4 years of age, she ran, spoke three- to four-word 
sentences, and understood what was said to her. Her muscle tone 
was slightly decreased, and she had weak reflexes. Her eye exam­
ination revealed mild strabismus.
P.L.
P.L. was the male child of nonconsanguineous American par­
ents of European heritage. At 4 months of age, lethargy devel­
oped, which was associated with emesis, hypotonia, and a dis­
tended bladder.
At examination, his weight was in the 5th percentile, height 
was in the 10th percentile, and head circumference was in the 60th 
percentile. He was thin and pale, with a marked absence of sub­
cutaneous fat. Motor examination revealed marked truncal and 
appendicular hypotonia; however, no atrophy or fasciculations
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were seen. Deep-tendon reflexes could not be elicited. An EEG, 
MRI, and EMG nerve conduction studies were normal.
After diagnosis, the 4-month-old started receiving vigabatrin at 
50 mg /kg per day, which was slowly increased during the sub­
sequent months to 100 mg/kg per day. The infant was clinically 
reevaluated at 13 months of age and found to be thriving. His 
weight was in the 91st percentile, height was in the 93rd percen­
tile, and head circumference was in the 65th percentile. Neurolog- 
ically, there was no evidence of hypotonia, and his examination 
results were nonfocal. Develo pin en tally, he was sitting without 
support and eating both formula and baby foods. He could reach 
for and transfer objects, clap his hands, and say a few nonspecific 
words.
P.S.H. (Note: Diagnosis Deduced After Death Because 
of Two Affected Siblings)
P.S.H. was the first child born to a nonconsanguineous Indian 
couple. The mother had a slight build and a somewhat unstable, 
atactic gait. At 3 months, PSH had poor head control and general 
muscular hypotonia. At 11 months, the child sat alone but had 
poor reflexes. The EEGs revealed multifocal discharges.
The patient began having absence seizures at 2 years of age. 
Psychomotor development was severely delayed; the child stood 
alone at 18 months of age, walked alone at 2Vi years of age, and 
spoke only one or two words by 3 years of age. The parents 
reported that the child was restless, had difficulty concentrating, 
and often missed objects when attempting to grab them.
Examination and clinical studies revealed no neurodegenera­
tive or metabolic disorders. Treatment with valproic acid resulted 
in increased alertness and balance, and seizures became less fre­
quent and finally ceased. The valproic acid treatment was discon­
tinued at 10 years of age after 5 seizure-free years. Approximately
1 year later, generalized epileptic seizures recurred and continued 
with increasing frequency. The child rapidly lost all psychomotor 
abilities and died at 13!/2 years of age.
P.S.
P.S., the younger female sibling of P.S.H., presented at 9V* years 
for evaluation. During her first few months, she reportedly had 
delayed motor development, poor head control, and general mus­
cular hypotonia. She sat alone at 12 months, stood at 18 months, 
and walked at 30 months.
She began having absence seizures at 4Vz years of age; phéno­
barbital briefly reduced the frequency of the seizures. Grand mal 
seizures started when the patient was 7 years old and were treated 
with valproic acid.
At examination, the patient was friendly arvd alert and tried to 
follow simple directions, but she was restless and unable to con­
centrate. She spoke only one or two words. The patient's skeletal 
age was retarded by VA years compared with her chronologic age 
of 9Vi years. She walked with an atactic and uncoordinated gait 
and could not climb stairs on her own. She had poor fine-motor 
ability with marked flaccidity, general muscular hypotonia, and 
hyporeflexia.
The EEG had an abnormal background rhythm and continuous 
/3 activity with generalized, irregular spike wave discharges. In 
addition, multifocal discharges, with separate foci seen over both 
hemispheres, were enhanced by intense photic stimulation. Diag­
nosis was made because of sibling P.V.
MRI of her brain revealed no abnormalities at 10V2 years of age. 
Menarche was at 113A years of age. At 13l/2 years, her physical 
development was normal, and her height and weight were in the 
25th percentile. There was no further intellectual development, 
and she was not able to speak, with the exception of a few 
incomprehensible syllable duplications. She was still unable to 
follow simple commands, which primarily was because of her 
severe hyperactivity and limited attention span. She attended a 
special school for severely retarded children. Her ataxia has not 
progressed, although she has a wide-based gait. There was no 
more seizure activity with the increased dosage of valproic acid 
(40 mg/kg per day) beginning September 1994, The EEG has a 
slightly abnormal background activity but no more discharges 
and no pathologic reaction to photic stimulation. The initial dos­
age of vigabatrin was 20 m g/kg per day and was increased during 
a period of IV2 years to 40 m g/kg per day. During this time, there 
was no improvement in intellectual ability or behavior. Treatment
was discontinued because of disturbing hypersalivation and in­
creasing sleepiness during the day.
P.V.
P.V. presented at 3 years of age. The female sibling of patients 
P.S. and P.S.H., she was born prematurely at 29 weeks after an 
uneventful pregnancy. During early infancy, feeding problems 
developed that have continued to the present. Psychomotor de­
velopment was notably delayed; she sat alone by 12 months but 
could not stand alone by 3 years of age. The patient was unable to 
speak at 3 years of age; however, she reacted to sound and seemed 
to understand but was unable to follow simple directions. Ab­
sence seizures developed at 2Vi years of age.
Physical examination revealed her weight at the 3rd percentile, 
height at the 25th percentile, and head circumference below the 
3rd percentile. She had general muscular hypotonia, flaccidity, 
and hyporeflexia. The EEG showed an abnormal background 
rhythm with bilateral, irregular, multifocal spike wave discharges. 
In addition, sharp, slow-wave foci were seen over the left hemi­
sphere. In general, there was no change in the EEG and discharge 
patterns during the next 4 i/2 years. At 6 years of age, CT of the 
head revealed no abnormalities.
At réévaluation at the age of 7Vi years, she was microcephalia 
(<3rd percentile), and her height and weight were in the 25th and 
3rd percentiles, respectively. She could hear but had no speech 
development. She was unable to follow simple commands. She 
had minimal motor development improvement; although she 
crawled well and pulled to stand, she could not stand or walk 
alone. Restlessness and hyperactivity developed, which limited 
her concentration. She attended a special school for severely re­
tarded children. She has had no grand mal seizures but has had 
frequent (daily) absence seizures and myoclonic absence seizures. 
The seizure frequency could be reduced by treatment with val­
proic acid and ethosuximide. Vigabatrin treatment has not been 
attempted.
T A .
T.A. was born after a pregnancy complicated by spotting at 
5 months and treated with bed rest. The mother also had a 
11/2-pack-per-day smoking habit. The consanguineous (first 
cousins) Lebanese parents had two other children, a 16-year-old 
and a 14-year-old, who were healthy.
As an infant, the patient had trismus and periodic episodes of 
stiffening, with his head turning to the left and possible bnck 
arching. His motor development was delayed; he sat alone at V/i 
years, crawled at 2 years, and walked alone at 4 years. His gait was 
unstable, with frequent falls. He had a diagnosis of cerebral palsy.
At 1 year of age he was hospitalized for vomiting, fever, and 
possible dehydration, Neurologic evaluation at 2 years of age 
attributed his psychomotor retardation to multigenic inheritance 
because of the parents' consanguinity. His speech development 
and comprehension were slow, and his vocabulary was limited to 
single words, He finger fed and used a cup by 3 years of age, but 
he did not use a spoon until 5 years of age. He followed simple 
commands at 3V2 years of age and began to combine words at 4 
years of age. He was toilet trained and tried, with difficulty, to 
dress himself.
Two EEGs and MRI were normal. Cranial CT raised the ques­
tion of cerebellar atrophy and enlargement of the lateral left ven­
tricle.
Developmental evaluation at 6% years of age revealed a boy 
who was pleasant, social, and vocal. He had a broad face with 
prominent ears. Neurologic examination showed striking truncal 
ataxia with walking and some instability when sitting or using the 
arms or legs, He had a wide-based gait and a tendency to stagger 
and fall. He had mild, generalized hypotonia, decreased muscle 
strength, and hyporeflexia. His speech was unclear, and he spoke 
in very short sentences. Developmental testing revealed mild to 
moderate mental retardation.
Y.A.
Y.A. was born to consanguineous Turkish parents. His psy- 
chomotor development was delayed; he sat at 12 months, stood at 
14 months, and walked at 28 months. Speech development also 
was delayed, with his first words at 3 years. Developmental 
testing revealed severe retardation.
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Neurologic examination revealed convergent strabismus, gen­
eralized hypotonia without ataxia, and normal deep-tendon re­
flexes. CT of the brain and an EMG showed no abnormalities.
He had multiple episodes of clouded consciousness, shouting, 
and abnormal behavior occurring between the ages of 2 and 3Vz 
years. These episodes generally occurred with fever and were 10 
to 15 minutes in duration. His EEG revealed hypo functional ab­
normalities, especially posteriorly; however, no epileptic abnor­
malities were found.
Vigabatrin therapy (50 mg/kg) was initiated at 27 months of 
age and was increased to 100 mg/kg at 37 months of age. There 
have been no clear clinical effects of the vigabatrin.
DISCUSSION
The presenting problem varied among the patients 
studied; however, in general, the presenting symp­
toms were neurologic (Table). The following present­
ing signs were observed: motor delay, 14 patients; 
hypotonia, 10 patients; mental delay, 9 patients; lan­
guage delay, 6 patients; ataxia, 3 patients; seizures, 2 
patients; and neonatal problems, 1 patient. All of the 
patients presented with one (or more) of these symp­
toms for which the parents sought help. The Table 
verifies the wide range of phenotypic presentation. 
Even in sibships, the disease presentation is not com­
pletely consistent. For example, J.I.Y. had hyperkine­
sis, which was not observed in the younger sibling, 
whereas the younger sibling, J.E.Y., had evidence of 
hypotonia not seen in her older sibling. In a sibship 
of three patients, however, the phenotype was very 
consistent. The lack of a clear-cut presenting pheno­
type and the significant variability in overall presen­
tation further underscores the variable nature of 
SSADH deficiency and the relative likelihood that 
the disorder is frequently undiagnosed or even mis­
diagnosed.
In our patients, we tabulated the following de­
scents: Turkish, 4; white American, 4; Northern 
European (German, Dutch, and Bulgarian), 3; Indian, 
3; Palestinian (Lebanese), 2; Korean, 2; Syrian 1; 
Saudi, 1; Inuit (Greenland), 1; Pakistani 1; and Chi­
nese, 1. To date, we know of no patients detected 
with SSADH deficiency who are in South America or 
Africa. One of the first patients in whom SSADH 
deficiency was diagnosed was thought to have orig­
inated from Algeria,5 but it is unclear whether he was 
French or Algerian by birth. Thus, SSADH deficiency 
seems to be primarily a disorder of the Eurasian 
region. Whether a founder effect can be linked to the 
disease remains to be determined. On the other 
hand, this may simply reflect more efficient meta­
bolic screening of the pediatric population for inher­
ited disease in the Northern European region. Ap­
proximately 40% of the probands in this report are 
offspring of consanguineous parents, a very high 
incidence of consanguinity. This may account for a 
Middle Eastern predominance in the geographic dis­
tribution of patients because of cultural habits. On 
the other hand, it may imply that disease-related 
alleles are rare in the human population. A high 
incidence of consanguinity is also consistent with 
multiple loci, but this will be addressed through 
molecular genetic studies.
At this time, it is difficult to assess whether "dis­
tinct" or "variant" forms of SSADH deficiency dis­
ease exist, because the patient population is still too
small. The SSADH gene is single copy and has been 
mapped to chromosome 6p23.7 However, until we 
have determined through molecular analysis that the 
disease maps to this locus in each patient, it remains 
preferable to refer to variant forms of SSADH defi­
ciency. We do not know whether modifier loci have 
a role, and it remains possible that heterogeneity 
may be more than allelic.
One intriguing finding in the tabulation of our 
patients is the possible distinction of early- and late- 
onset forms of SSADH deficiency, or at least forms of 
the disease differentiated by development during 
infancy. Remarkably, the Table verifies that 7 of 23 
patients had normal early development. This is not 
to say that the ensuing clinical course in these puta­
tive "late-onset" patients is mild. Moreover, it is 
difficult to identify any one factor as the cause of the 
late-onset disease form. Molecular genetic analyses 
eventually may provide answers to these questions. 
Another interesting observation is the fact that ther­
apeutic intervention with the GAB A transaminase 
inhibitor vigabatrin was only clinically beneficial in 
about one third of patients (Table).
The lack of therapeutic efficacy with vigabatrin is 
of interest. Therapeutic efficacy may again reflect 
heterogeneity at the genetic or enzymic level. On the 
other hand, Howells and colleagues8 have suggested 
that vigabatrin has limited use in SSADH deficiency 
because of differential effects on organ specific 
GAB A transaminases. These investigators postulated 
that although vigabatrin may inhibit brain GAB A 
transaminase effectively, limited inhibition of pe- 
ripheral organ GAB A transaminases could lead to 
resupply of 4-hydroxybutyric acid across the blood- 
brain barrier, thereby decreasing the clinical efficacy 
of therapeutic intervention in the central nervous 
system.
Intervention with high-dose vigabatrin actually 
had deleterious effects in one patient. Accordingly, 
Matern and colleagues6 found that titrating the viga­
batrin dose to a clinically beneficial level was pru­
dent in their patient with SSADH deficiency. High 
levels of vigabatrin (75 to 100 m g/kg per day) in­
duced electroencephalographic abnormalities and 
seizure activity in this patient, whereas lower levels 
(25 m g/kg per day) were beneficial For future ref­
erence, physicians treating patients with SSADH de­
ficiency may wish to administer vigabatrin in in­
creasing quantities. Interestingly, in the three 
patients for whom L-carnitine levels were evaluated, 
the plasma levels were low (Table), and carnitine 
therapy in M.W. dramatically improved muscle tone. 
Therefore, L-carnitine intervention should be consid­
ered in SSADH deficiency if plasma carnitine levels 
are low.
This review of 23 new SSADH-deficient patients 
clearly demonstrates that the clinical phenotype is 
extremely nonspecific, which suggests that the dis­
order is significantly underdiagnosed. It is likely that 
all patients with SSADH deficiency will manifest 
some degree of psychomotor deficit within their 
childhood years; however, speech and langttage de­
lay and hypotonia are not necessary concomitants of 
the disorder, as previously thought. Although the
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findings varied, delayed psychomotor and language 
development and hypotonia were observed in ap­
proximately three fourths of the patients. Notable 
exceptions were I.C. and A.F. (the latter an adult 
patient who attended primary school), both of whom 
had normal development of speech and language. 
The detection of seizures in half of the patients was 
surprising, because seizures were not previously 
thought to be prevalent in SSADH deficiency. On the 
other hand, the detection of ataxia in only one third 
of patients was surprising, because ataxia was pre­
viously thought to be common in SSADH deficiency. 
The inability to diagnose SSADH deficiency is exem­
plified in A.R, in whom the correct diagnosis was not 
achieved until 25 years of age. Interestingly, this man 
represents only the second adult patient in whom 
SSADH deficiency has been diagnosed.9
In addition to a nonspecific clinical presentation, 
other features of SSADH deficiency may often con­
found the correct differential diagnosis. Patients with 
SSADH deficiency do not present with the usual 
concomitants of an inborn error of metabolism. There 
is no metabolic acidosis, hyperammonemia, hypo­
glycemia, growth retardation, or episodic decompen­
sation with vomiting and/or lethargy often seen in 
other inborn errors of metabolism. In addition, the 
characteristic metabolite in the disorder, 4-hydroxy- 
butyric acid, can elude accurate quantitation because 
of its ability to lactonize and volatilize. The essential 
feature for diagnosis of SSADH deficiency is 4-hy- 
droxybutyric aciduria. However, there has not been 
100% concordance between metabolite excretion and 
enzyme deficiency thus far, although the percentage 
is very high. We are aware of at least two patients 
who have excreted small amounts of 4-hydroxybu- 
tyric acid with normal SSADH activity. These pa­
tients must be followed to assess whether metabolite 
excretion persists. To avoid loss of 4-hydroxybutyric 
acid after routine acid extraction of urine, clinical 
laboratories should use extreme caution in removal 
of solvent. We have found it worthwhile to alkalinize 
acidic extracts of urine to at least pH 5 after acidic 
extraction to avoid substantial loss of 4-hydroxybu­
tyric acid. Moreover, gas chromatographic analysis 
alone is insufficient to detect small elevations in 
urine; mass spectrometric analysis is essential for 
correct diagnosis. We and others use isotope-dilution 
methods for metabolite quantification in physiologic 
fluids from patients with 4-hydroxybutyric aciduria, 
which is the most accurate approach for quantita­
tion.9
Several specialist laboratories have considerable 
expertise in accurately diagnosing SSADH deficiency 
through organic acid analysis. Our recommendation 
would be that accurate, quantitative, urine organic 
acid analysis be requested for any patient presenting 
with two or more features of mental, motor, or lan­
guage delay and hypotonia of unknown cause. Such 
analyses are the only definitive way to diagnose 
SSADH deficiency; the diagnosis can be confirmed 
by determination of enzyme activity in white cells 
from whole blood. We think that increased use of 
organic acid analysis will lead to increased diagnosis 
of SSADH deficiency, which will result in a more 
accurate representation of the disease frequency. As 
additional patients are identified, we should have a 
better understanding of both the metabolic and clin­
ical profile of SSADH deficiency.
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